Loading...
The University of Chicago Header Logo
Keywords
Last Name
Institution

Randy Sweis

TitleAssistant Professor
InstitutionUniversity of Chicago
DepartmentMedicine-Hematology and Oncology
AddressChicago IL 60637
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    Dr. Sweis is a physician-scientist working to identify and circumvent mechanisms of resistance to cancer immunotherapies. His laboratory research is focused on modulating the tumor microenvironment to facilitate anti-tumor immune responses, using mouse models of bladder and skin cancers. In the clinic, he uses his expertise in developmental therapeutics and clinical pharmacology to investigate biomarkers and novel therapeutic strategies to improve immunotherapy efficacy in patients.


    Collapse ORNG Applications 
    Collapse Featured Presentations
    Collapse Twitter

    Collapse Research 
    Collapse research activities and funding
    K08CA234392     (SWEIS, RANDY F.)Sep 10, 2018 - Aug 31, 2022
    NIH
    Elucidating immunotherapy resistance mechanisms in non-T cell-inflamed bladder cancer
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Lee CH, Shah AY, Rasco D, Rao A, Taylor MH, Di Simone C, Hsieh JJ, Pinto A, Shaffer DR, Girones Sarrio R, Cohn AL, Vogelzang NJ, Bilen MA, Gunnestad Ribe S, Goksel M, Tennøe ØK, Richards D, Sweis RF, Courtright J, Heinrich D, Jain S, Wu J, Schmidt EV, Perini RF, Kubiak P, Okpara CE, Smith AD, Motzer RJ. Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study. Lancet Oncol. 2021 07; 22(7):946-958. PMID: 34143969.
      View in: PubMed
    2. Richard G, De Groot AS, Steinberg GD, Garcia TI, Kacew A, Ardito M, Martin WD, Berdugo G, Princiotta MF, Balar AV, Sweis RF. Multi-step screening of neoantigens' HLA- and TCR-interfaces improves prediction of survival. Sci Rep. 2021 05 11; 11(1):9983. PMID: 33976291.
      View in: PubMed
    3. Quandt J, Arnovitz S, Haghi L, Woehlk J, Mohsin A, Okoreeh M, Mathur PS, Emmanuel AO, Osman A, Krishnan M, Morin SB, Pearson AT, Sweis RF, Pekow J, Weber CR, Khazaie K, Gounari F. Wnt-ß-catenin activation epigenetically reprograms Treg cells in inflammatory bowel disease and dysplastic progression. Nat Immunol. 2021 04; 22(4):471-484. PMID: 33664518.
      View in: PubMed
    4. Sayaman RW, Saad M, Thorsson V, Hu D, Hendrickx W, Roelands J, Porta-Pardo E, Mokrab Y, Farshidfar F, Kirchhoff T, Sweis RF, Bathe OF, Heimann C, Campbell MJ, Stretch C, Huntsman S, Graff RE, Syed N, Radvanyi L, Shelley S, Wolf D, Marincola FM, Ceccarelli M, Galon J, Ziv E, Bedognetti D. Germline genetic contribution to the immune landscape of cancer. Immunity. 2021 02 09; 54(2):367-386.e8. PMID: 33567262.
      View in: PubMed
    5. Kacew A, Sweis RF. FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer. Front Immunol. 2020; 11:575258. PMID: 33224141.
      View in: PubMed
    6. Han L, Gallan AJ, Steinberg GD, Sweis RF, Paner GP. Morphological correlation of urinary bladder cancer molecular subtypes in radical cystectomies. Hum Pathol. 2020 12; 106:54-61. PMID: 32987034.
      View in: PubMed
    7. Andolfi C, Bloodworth JC, Papachristos A, Sweis RF. The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness. Bladder Cancer. 2020 Sep 21; 6(3):225-235. PMID: 33195783.
      View in: PubMed
    8. Hatogai K, Sweis RF. The Tumor Microenvironment of Bladder Cancer. Adv Exp Med Biol. 2020; 1296:275-290. PMID: 34185299.
      View in: PubMed
    9. Apolo AB, Milowsky MI, Kim L, Inman BA, Kamat AM, Steinberg G, Bagheri M, Krishnasamy VP, Marko J, Dinney CP, Bangs R, Sweis RF, Maher VE, Ibrahim A, Liu K, Werntz R, Cross F, Beaver JA, Singh H, Pazdur R, Blumenthal GM, Lerner SP, Bajorin DF, Rosenberg JE, Agrawal S. Eligibility and Radiologic Assessment in Adjuvant Clinical Trials in Bladder Cancer. JAMA Oncol. 2019 12 01; 5(12):1790-1798. PMID: 31670753.
      View in: PubMed
    10. Sweis RF. Methods to assess anticancer immune responses in orthotopic bladder carcinomas. Methods Enzymol. 2020; 635:127-137. PMID: 32122541.
      View in: PubMed
    11. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Correction to: Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 Jul 04; 7(1):167. PMID: 31272507.
      View in: PubMed
    12. Bedognetti D, Ceccarelli M, Galluzzi L, Lu R, Palucka K, Samayoa J, Spranger S, Warren S, Wong KK, Ziv E, Chowell D, Coussens LM, De Carvalho DD, DeNardo DG, Galon J, Kaufman HL, Kirchhoff T, Lotze MT, Luke JJ, Minn AJ, Politi K, Shultz LD, Simon R, Thórsson V, Weidhaas JB, Ascierto ML, Ascierto PA, Barnes JM, Barsan V, Bommareddy PK, Bot A, Church SE, Ciliberto G, De Maria A, Draganov D, Ho WS, McGee HM, Monette A, Murphy JF, Nisticò P, Park W, Patel M, Quigley M, Radvanyi L, Raftopoulos H, Rudqvist NP, Snyder A, Sweis RF, Valpione S, Zappasodi R, Butterfield LH, Disis ML, Fox BA, Cesano A, Marincola FM. Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop. J Immunother Cancer. 2019 05 22; 7(1):131. PMID: 31113486.
      View in: PubMed
    13. Pearson AT, Sweis RF. Hyperprogression-Immunotherapy-Related Phenomenon vs Intrinsic Natural History of Cancer. JAMA Oncol. 2019 05 01; 5(5):743. PMID: 30896751.
      View in: PubMed
    14. Labbate C, Hatogai K, Werntz R, Stadler WM, Steinberg GD, Eggener S, Sweis RF. Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy. J Immunother Cancer. 2019 03 11; 7(1):66. PMID: 30857555.
      View in: PubMed
    15. Luke JJ, Bao R, Sweis RF, Spranger S, Gajewski TF. WNT/ß-catenin Pathway Activation Correlates with Immune Exclusion across Human Cancers. Clin Cancer Res. 2019 May 15; 25(10):3074-3083. PMID: 30635339.
      View in: PubMed
    16. Leng J, Akthar AS, Szmulewitz RZ, O'Donnell PH, Sweis RF, Pitroda SP, Smith N, Steinberg GD, Liauw SL. Safety and Efficacy of Hypofractionated Radiotherapy With Capecitabine in Elderly Patients With Urothelial Carcinoma. Clin Genitourin Cancer. 2019 Feb; 17(1):e12-e18. PMID: 30392939.
      View in: PubMed
    17. Trujillo JA, Sweis RF, Bao R, Luke JJ. T Cell-Inflamed versus Non-T Cell-Inflamed Tumors: A Conceptual Framework for Cancer Immunotherapy Drug Development and Combination Therapy Selection. Cancer Immunol Res. 2018 09; 6(9):990-1000. PMID: 30181337.
      View in: PubMed
    18. Drazer MW, Sweis RF. Low clinical adoption of tumor genomic profiling: cause for concern? J Med Econ. 2018 Jul; 21(7):721-723. PMID: 29708449.
      View in: PubMed
    19. Sweis RF, Zha Y, Pass L, Heiss B, Chongsuwat T, Luke JJ, Gajewski TF, Szmulewitz R. Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer. J Immunother Cancer. 2018 04 04; 6(1):24. PMID: 29618376.
      View in: PubMed
    20. Sanagapalli S, Emmanuel A, Leong R, Kerr S, Lovat L, Haidry R, Banks M, Graham D, Raeburn A, Zarate-Lopez N, Sweis R. Impaired motility in Barrett's esophagus: A study using high-resolution manometry with physiologic challenge. Neurogastroenterol Motil. 2018 Mar 15. PMID: 29542847.
      View in: PubMed
    21. Sweis RF, Luke JJ. Mechanistic and pharmacologic insights on immune checkpoint inhibitors. Pharmacol Res. 2017 Jun; 120:1-9. PMID: 28323141.
      View in: PubMed
    22. Sweis RF, Galsky MD. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers. Urol Oncol. 2016 12; 34(12):556-565. PMID: 27836246.
      View in: PubMed
    23. Sweis RF, Ratain MJ. Obviating the Need for Serial Biopsies Through Random Assignment. J Clin Oncol. 2017 01 10; 35(2):260. PMID: 28056195.
      View in: PubMed
    24. Sweis RF, Medved M, Towey S, Karczmar GS, Oto A, Szmulewitz RZ, O'Donnell PH, Fishkin P, Karrison T, Stadler WM. Dynamic Contrast-Enhanced Magnetic Resonance Imaging as a Pharmacodynamic Biomarker for Pazopanib in Metastatic Renal Carcinoma. Clin Genitourin Cancer. 2017 04; 15(2):207-212. PMID: 27634566.
      View in: PubMed
    25. Sweis RF, Spranger S, Bao R, Paner GP, Stadler WM, Steinberg G, Gajewski TF. Molecular Drivers of the Non-T-cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer. Cancer Immunol Res. 2016 07; 4(7):563-8. PMID: 27197067.
      View in: PubMed
    26. Sweis RF, Ratain MJ. Reply to T.A. Yap et al. J Clin Oncol. 2016 07 10; 34(20):2432-3. PMID: 27138578.
      View in: PubMed
    27. Sweis RF, Thomas S, Bank B, Fishkin P, Mooney C, Salgia R. Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer. Cureus. 2016 Feb 26; 8(2):e513. PMID: 27026837.
      View in: PubMed
    28. Sweis RF, Drazer MW, Ratain MJ. Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. J Clin Oncol. 2016 Feb 01; 34(4):369-74. PMID: 26668350.
      View in: PubMed
    29. Chopra V, Govindan S, Kuhn L, Ratz D, Sweis RF, Melin N, Thompson R, Tolan A, Barron J, Saint S. Do clinicians know which of their patients have central venous catheters?: a multicenter observational study. Ann Intern Med. 2014 Oct 21; 161(8):562-7. PMID: 25329204.
      View in: PubMed
    30. Sweis R, Kaufman E, Anggiansah A, Wong T, Dettmar P, Fried M, Schwizer W, Avvari RK, Pal A, Fox M. Post-prandial reflux suppression by a raft-forming alginate (Gaviscon Advance) compared to a simple antacid documented by magnetic resonance imaging and pH-impedance monitoring: mechanistic assessment in healthy volunteers and randomised, controlled, double-blind study in reflux patients. Aliment Pharmacol Ther. 2013 Jun; 37(11):1093-102. PMID: 23600790.
      View in: PubMed
    31. Pitroda SP, Zhou T, Sweis RF, Filippo M, Labay E, Beckett MA, Mauceri HJ, Liang H, Darga TE, Perakis S, Khan SA, Sutton HG, Zhang W, Khodarev NN, Garcia JG, Weichselbaum RR. Tumor endothelial inflammation predicts clinical outcome in diverse human cancers. PLoS One. 2012; 7(10):e46104. PMID: 23056240.
      View in: PubMed
    32. Sweis RF, Propes MJ, Hyjek E. Actinomyces-induced inflammatory pseudotumor of the lymph node mimicking scrofula. Ann Intern Med. 2011 Jul 05; 155(1):66-7. PMID: 21727298.
      View in: PubMed
    33. Sweis RF, Schramm MP, Kozmin SA. Silver-catalyzed [2 + 2] cycloadditions of siloxy alkynes. J Am Chem Soc. 2004 Jun 23; 126(24):7442-3. PMID: 15198582.
      View in: PubMed
    34. Denmark SE, Sweis RF. Fluoride-free cross-coupling of organosilanols. J Am Chem Soc. 2001 Jul 04; 123(26):6439-40. PMID: 11427080.
      View in: PubMed
    Sweis's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description
    Physical Neighbors Expand Description
    _